clinical trial · NCT06842355
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
AchondroplasiaTYRA-300 0.125 mg/kgTYRA-300 0.25 mg/kgTYRA-300 0.375 mg/kgTYRA-300 0.50 mg/kg
brief summary
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
started
Mar 4, 2025
primary completion
Jan 1, 2030
completion
Jun 1, 2030
last updated
Apr 24, 2026
detailed description
This is a Phase 2, multicenter, open-label, dose-escalation study to determine the safety, tolerability, and identify potentially effective dose(s) of TYRA-300, a fibroblast growth factor receptor (FGFR)-3 selective tyrosine kinase inhibitor, in children 3 to 10 years of age with achondroplasia with open growth plates that will examine three cohorts of children: the Sentinel Safety Cohort, Cohort 1, and Cohort 2.
official title
A Multicenter, Phase 2, Dose-Escalation/Dose-Expansion Study of TYRA-300 in Children With Achondroplasia With Open Growth Plates: BEACH301
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol